ADMA Biologics
ADMA
113 hedge funds and large institutions have $236M invested in ADMA Biologics in 2022 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 26 closing their positions.
142% more call options, than puts
Call options by funds: $1.47M | Put options by funds: $607K
35% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 26
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
24% more capital invested
Capital invested by funds: $190M → $236M (+$46.4M)
19% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 26
8% more funds holding
Funds holding: 105 → 113 (+8)
7.18% more ownership
Funds ownership: 53.54% → 60.72% (+7.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$16.7M |
| 2 |
D.E. Shaw & Co
New York
|
+$5.76M |
| 3 |
Millennium Management
New York
|
+$4.98M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.59M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
-$5.95M |
| 2 |
CC
Clearline Capital
New York
|
-$4.37M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.51M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.67M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$1.35M |
ADMA Hedge Fund Activity: Q2 2022 in Review
113 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q2 2022, worth a combined $236M — up 24% from $190M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ADMA positions and 26 closed out — a net gain of 9 holders — while 31 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock, adding an estimated $16.7M. The largest seller was Maven Securities, cutting an estimated $5.95M.
- 113 institutional investors held ADMA Biologics (ADMA) as of Q2 2022, up from 105 in Q1 2022.
- Funds reported $236M of ADMA Biologics stock for Q2 2022, up 24% quarter-over-quarter.
- 35 funds opened new ADMA Biologics positions in Q2 2022 and 26 closed out, a net change of +9 holders.
- The largest ADMA Biologics buyer in Q2 2022 was BlackRock, an estimated $16.7M added.
- The largest ADMA Biologics seller in Q2 2022 was Maven Securities, an estimated $5.95M sold.
Based on aggregated 13F filings for Q2 2022.